Superior Planning, LLC’s Compass Therapeutics CMPX Stock Holding History

Superior Planning, LLC’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.54K	Buy	+2,440	New	+$5.03K	﹤0.01%	1479

Other funds holding CMPX

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Superior Planning, LLC's CMPX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Compass Therapeutics (CMPX) in Q3 2026: 2,440 shares worth $2.54K. The stake represents ﹤0.01% of the portfolio and ranks #1479 among its holdings.

87 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

Superior Planning, LLC held 2,440 shares of Compass Therapeutics worth $2.54K as of Q3 2026.
Compass Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Compass Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1479 holding.
87 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.